Unfortunately, limited evidence has been accumulated in HCC except that PD-L1 expression by both neoplastic or intratumoral inflammatory cells is related to tumor aggressiveness and suggests clinical benefits when using ICIs targeting PD-1/PD-L1 signaling using a retrospective HCC cohort (17). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.